Elizabeth Weesner, et al. “Injection Site Reaction to Extended-Release Buprenorphine (Sublocade®) for Opioid Use Disorder Fourteen Days After Administration”. Kansas Journal of Medicine, vol. 15, no. 2, Aug. 2022, pp. 302-4, https://doi.org/10.17161/kjm.vol15.17931.